JPWO2023018237A5 - - Google Patents

Info

Publication number
JPWO2023018237A5
JPWO2023018237A5 JP2024507883A JP2024507883A JPWO2023018237A5 JP WO2023018237 A5 JPWO2023018237 A5 JP WO2023018237A5 JP 2024507883 A JP2024507883 A JP 2024507883A JP 2024507883 A JP2024507883 A JP 2024507883A JP WO2023018237 A5 JPWO2023018237 A5 JP WO2023018237A5
Authority
JP
Japan
Prior art keywords
cancer
alkyl
ring
pharmaceutically acceptable
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530495A5 (https=
JP2024530495A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2022/011962 external-priority patent/WO2023018237A1/en
Publication of JP2024530495A publication Critical patent/JP2024530495A/ja
Publication of JPWO2023018237A5 publication Critical patent/JPWO2023018237A5/ja
Publication of JP2024530495A5 publication Critical patent/JP2024530495A5/ja
Pending legal-status Critical Current

Links

JP2024507883A 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物 Pending JP2024530495A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
KR20210105358 2021-08-10
KR10-2021-0105358 2021-08-10
KR20210106488 2021-08-12
KR10-2021-0106488 2021-08-12
KR10-2021-0117389 2021-09-03
KR20210117389 2021-09-03
KR10-2021-0126757 2021-09-24
KR20210126757 2021-09-24
KR20220008456 2022-01-20
KR10-2022-0008456 2022-01-20
KR20220020996 2022-02-17
KR10-2022-0020996 2022-02-17
KR20220054880 2022-05-03
KR10-2022-0054880 2022-05-03
KR20220075838 2022-06-21
KR10-2022-0075838 2022-06-21
PCT/KR2022/011962 WO2023018237A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound

Publications (3)

Publication Number Publication Date
JP2024530495A JP2024530495A (ja) 2024-08-21
JPWO2023018237A5 true JPWO2023018237A5 (https=) 2025-08-13
JP2024530495A5 JP2024530495A5 (https=) 2025-08-13

Family

ID=85200656

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023514160A Active JP7555156B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507883A Pending JP2024530495A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2023514149A Active JP7555155B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023514160A Active JP7555156B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023514149A Active JP7555155B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物

Country Status (15)

Country Link
US (4) US11939334B2 (https=)
EP (4) EP4157849A4 (https=)
JP (4) JP7555156B2 (https=)
KR (5) KR102604803B1 (https=)
CN (2) CN116322700B (https=)
AU (1) AU2022327025A1 (https=)
CA (1) CA3228601A1 (https=)
CL (1) CL2024000373A1 (https=)
CO (1) CO2024001256A2 (https=)
CR (1) CR20240120A (https=)
EC (1) ECSP24010109A (https=)
IL (1) IL310678A (https=)
MX (1) MX2024001774A (https=)
PE (1) PE20240894A1 (https=)
WO (5) WO2023018236A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
CN120603831A (zh) * 2022-11-29 2025-09-05 厄普特拉株式会社 具有增加的刚性的plk1降解诱导化合物
KR20250037591A (ko) * 2023-02-02 2025-03-17 (주) 업테라 신규 plk1 분해 유도 화합물
WO2024188209A1 (zh) * 2023-03-10 2024-09-19 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
KR20260022390A (ko) 2023-06-08 2026-02-19 누릭스 테라퓨틱스 인코포레이티드 Smarca2의 선택적 분해제로서의 이작용성 아진 접합체 및 이의 치료적 용도
CN121816348A (zh) 2023-08-11 2026-04-07 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途
WO2025062330A1 (en) 2023-09-20 2025-03-27 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
WO2025125575A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN118724841A (zh) * 2024-06-14 2024-10-01 南通华祥医药科技有限公司 一种n-氨基哌啶二盐酸盐的制备方法
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026026773A1 (zh) * 2024-07-29 2026-02-05 杭州胶联生物医药科技有限公司 作为vav1蛋白靶点降解剂的新型取代杂环类化合物
WO2026041138A1 (zh) * 2024-08-22 2026-02-26 武汉人福创新药物研发中心有限公司 作为vav1降解剂的苯并杂环类化合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649324A1 (en) * 2006-04-12 2007-10-25 Jean-Damien Charrier Tetrahydropteridines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008113711A1 (en) * 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016349781A1 (en) * 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
CN106543185B (zh) * 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
BR112019015484A2 (pt) * 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
CN106977584B (zh) 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
CN109879877B (zh) 2019-03-04 2021-08-10 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
AU2020356484A1 (en) * 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1

Similar Documents

Publication Publication Date Title
JPWO2023018237A5 (https=)
JP2019535744A5 (https=)
JP2019535746A5 (https=)
CN102816175B (zh) 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
JP2025160318A5 (https=)
JP2022062168A5 (https=)
DK2197878T3 (en) FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases
CN113316574A (zh) Shp2抑制剂及其应用
JP2008505167A5 (https=)
IL295603A (en) Protein compounds and their uses
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
CA2649549A1 (en) Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
JP2019517487A5 (https=)
KR20210075992A (ko) Sting 작동 화합물
JP2017537114A5 (https=)
JP2009513703A5 (https=)
JP2008521928A5 (https=)
RU2016147654A (ru) Соединения для лечения рака
JP2013538213A5 (https=)
EP3411121B1 (en) Glucose conjugates of triptolide, analogs and uses thereof
RU2013112871A (ru) Соединения для лечения рака
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
AU2015402778A2 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
RU2017129151A (ru) Производное резорцина в качестве ингибитора hsp90